Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

High-dose cisplatin concurrent to concentionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma (2007)

  • Authors:
  • USP affiliated authors: FERRAZ, ALBERTO ROSSETTI - FM ; FEDERICO, MIRIAM HATSUE HONDA - FM ; NADALIN, WLADIMIR - FM
  • USP Schools: FM; FM; FM
  • DOI: 10.1007/s00405-007-0395-9
  • Subjects: ANTINEOPLÁSICOS (ADMINISTRAÇÃO E DOSAGEM); NEOPLASIAS DE CABEÇA E PESCOÇO (RADIOGRAFIA;RADIOTERAPIA); CARCINOMA DE CÉLULAS ESCAMOSAS (QUIMIOTERAPIA)
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    DOI or search this record in
    Informações sobre o DOI: 10.1007/s00405-007-0395-9 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: European Archives of Oto-Rhino-Laryngology

    ISSN: 0937-4477

    Citescore - 2017: 1.54

    SJR - 2017: 0.8

    SNIP - 2017: 1.061


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FM10700090112-SFM BCBIB
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      CASTRO JUNIOR, Gilberto de; SNITCOVSKY, Moisés Longo; GEBRIM, Eloísa Maria Mello Santiago; et al. High-dose cisplatin concurrent to concentionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology and Head & Neck, New Jersey, v. 264, n. 12, p. 1475-1482, 2007. DOI: 10.1007/s00405-007-0395-9.
    • APA

      Castro Junior, G. de, Snitcovsky, M. L., Gebrim, E. M. M. S., Leitão, G. M., Nadalin, W., Ferraz, A. R., & Federico, M. H. H. (2007). High-dose cisplatin concurrent to concentionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology and Head & Neck, 264( 12), 1475-1482. doi:10.1007/s00405-007-0395-9
    • NLM

      Castro Junior G de, Snitcovsky ML, Gebrim EMMS, Leitão GM, Nadalin W, Ferraz AR, Federico MHH. High-dose cisplatin concurrent to concentionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology and Head & Neck. 2007 ; 264( 12): 1475-1482.
    • Vancouver

      Castro Junior G de, Snitcovsky ML, Gebrim EMMS, Leitão GM, Nadalin W, Ferraz AR, Federico MHH. High-dose cisplatin concurrent to concentionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology and Head & Neck. 2007 ; 264( 12): 1475-1482.

    Referências citadas na obra
    Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA (2003) An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98
    Cooper JS, Farnan NC, Asbell SO, Rotman M, Marcial V, Fu KK, McKenna WG, Emami B (1996) Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group studies of head and neck cancer. Cancer 77:1905–1911
    Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (2002) AJCC cancer staging handbook. 6th edn. Springer, New York
    Pignon JP, Bourhis J, Domenge C, Designé L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355:949–955
    Available at http://www.fosp.saude.sp.gov.br , accessed in June 23rd, 2006
    Bourhis J, Amand C, Pignon JP (2004) Update of MACH-NC (Meta-analysis of chemotherapy in head and neck cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 22(Suppl 14):5505
    Rosenthal DI, Ang KK (2004) Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma. Semin Radiat Oncol 14:153–166
    Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR (1998) Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798–1804
    Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G (2004) Final results of the 94–01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22:69–76
    Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, Pestalozzi B, Schmid S, Thoni A, Ozsahin M, Bernier J, Topfer M, Kann R, Meier UR, Thum P, Bieri S, Notter M, Lombriser N, Glanzmann C (2004) Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 22:4665–4673
    Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L (2000) Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18:1458–1464
    Merlano M, Benasso M, Corvò R, Rosso R, Vitale V, Blengio F, Numico G, Margarino G, Bonelli L, Santi L (1996) Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 88:583–589
    Wendt TG, Grabenbauer GG, Rödel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TPU, Iro H, Papella C, Schalhorn A (1998) Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16:1318–1324
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216
    Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113:9–19
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
    Suntharalingam M, Haas ML, Van Echo DA, Haddad R, Jacobs MC, Levy S, Gray WC, Ord RA, Conley BA (2001) Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer 91:548–554
    Vokes EE, Kies MS, Haraf DJ, Stenson K, List M, Humerickhouse R, Dolan ME, Pelzer H, Sulzen L, Witt ME, Hsieh YC, Mittal BB, Weichselbaum RR (2000) Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 18:1652–1661
    Eisbruch A, Normolle DP (2005) Testing new chemoradiation regimens for head-and-neck cancer. Int J Radiat Oncol Biol Phys 61:5–6
    Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7–16
    Withers HR, Taylor JM, Maciejewski B (1988) The harzard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27:131–146
    Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM (2005) Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 61:1087–1095
    Bourhis J, Le Maître A, Pignon J, Ang K, Bernier J, Overgaard J, Tobias J, Saunders M, Adelstein D, O’Sullivan B (2006) Impact of age on treatment effect in locally advanced head and neck cancer: two individual patient data meta-analyses. J Clin Oncol 24(Suppl 18):5501
    Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, Trott KR, Wilson GD (2005) Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23:5560–5567
    Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR (2005) Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6:757–764
    Eriksen JG, Alsner J, Steiniche T, Overgaard J (2005) The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times. Radiother Oncol 76:135–142
    de Castro G Junior, Federico MH (2006) Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients. Curr Opin Oncol 18:266–270
    Garden AS, Morrison WH, Rosenthal DI, Chao KS, Ang KK (2004) Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Semin Radiat Oncol 14:103–109
    Brizel DM, Le QT, Rosenthal D, Meredith R, Brizel HE, Heard R, Yao B, Eng T, Sailer S, Chen Y, Murphy B, Mendenhall W (2002) Phase 2 study of recombinant human keratinocyte growth factor (rHuKGF) in head and neck cancer treated with standard or hyperfractionated irradiation and concurrent chemotherapy. Int J Radiat Oncol Biol Phys 54(Suppl):285–286
    Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(Suppl 9):2026–2046
    Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maitre A, Pajak TF, Poulsen MG, O’Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843–854
    Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M, Bernier J, Lusinchi A, Stuschke M, Lopez-Torrecilla J, Begg AC, Pierart M, Collette L (1997) Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44:111–121
    Remenar E, Van Herpen C, Germa Lluch J, Stewart S, Gorlia T, Degardin M, Bernier J, Spirlet C, Vermorken JB (2006) A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck. Final analysis of EORTC 24971. J Clin Oncol 24(Suppl 18):5516
    Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Marti JL, Lobo F, Pastor P, Valenti V, Belon J, Sanchez MA, Chaib C, Pallares C, Anton A, Cervantes A, Paz-Ares L, Cortes-Funes H (2005) Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636–8645
    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578
    Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindelov B, Jorgensen K (1998) A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5–85. Radiother Oncol 46:135–146
    Rischin D, Peters L, Fisher R Macann A, Denham J, Poulsen M, Jackson M, Kenny L, Penniment M, Corry J, Lamb D, McClure B (2005) Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23:79–87
    Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF (2003) Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362:933–940
    Overgaard J, Mohanti BK, Bhasker S, Begum N, Ali R, Agerwal J, Kuddu M, Baeza M, Vikram B, Grau C (2006) Accelerated versus conventional fractionated radiotherapy in squamous cell carcinoma of the head and neck. A randomized international multicenter trial with 908 patients conducted by the IAEA-ACC Study Group. Int J Radiat Oncol Biol Phys 66(Suppl):13
    Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI: